

IPR and Innovation

1. [India's pharmaceutical patent law may face new hurdle](#) – Mint
2. [GSK and Save the Children launch 2015 call for developing country healthcare innovations to reduce child deaths](#) – Express Pharma

Access to Healthcare

1. [NPPA adds 39 more drugs to the controlled list](#) – Business Standard

Medical & Regulatory

1. [India's top court seeks review of drug pricing policy](#) – Reuters
2. [Medicines for diabetes, infections to cost 40% less](#) – The Times of India
3. [AdvaMed demands passage of D&C Amendment Bill to delineate medical devices from drugs](#) – Pharmabiz
4. [Grievances of chemists & druggists about DPCO-2013, Jan Aushadhi & online pharmacy are genuine: NPPA chief](#) – Pharmabiz.com

Others

1. [Digital health market in good shape, keeps VC funds flowing in](#) – The Business Line
2. [Bogus healthcare](#) – The Telegraph

IPR and Innovation

1. [India's pharmaceutical patent law may face new hurdle](#) - Mint
The patent law for pharmaceutical products in India and other developing countries, including provisions that define what constitutes inventions, could face a legal challenge because of a controversial new norm being pushed by the US and Switzerland. The norm, which would adversely affect Indian pharmaceutical companies, calls for applying non-violation complaints (NVCs) to the World Trade Organization's (WTO) trade-related intellectual property rights (TRIPS) agreement.
2. [GSK and Save the Children launch 2015 call for developing country healthcare innovations to reduce child deaths](#) – Express Pharma
This year's Healthcare Innovation Award seeks entries that demonstrate new approaches to increasing people's access to health services in developing countries. GSK and Save the Children announced the launch of their third annual \$1 million healthcare innovation award that rewards innovations in healthcare that have helped to reduce child deaths in developing countries.

Access to Healthcare

1. [NPPA adds 39 more drugs to the controlled list](#) – Business Standard
Expanding the number of [drugs](#) under control, the [National Pharmaceutical Pricing Authority](#) (NPPA) has added 39 more drugs meant to treat diabetes, infections and digestive disorders to

the list. The move is likely to impact drug makers such as Abbott Laboratories, Ipca Laboratories, Lupin, Cadila Healthcare and GlaxoSmithKline.

Medical & Regulatory

1. [India's top court seeks review of drug pricing policy](#) - Reuters
India's Supreme Court has asked the federal government to reexamine its pricing policy for essential medicines after a group of non-governmental organizations challenged the provisions, a lawyer involved in the case said.
2. [Medicines for diabetes, infections to cost 40% less](#) – The Times of India
Medicines widely used to treat diabetes, infections, pain and digestive disorders will cost 5-40% less with immediate effect, with the drug price regulator issuing an order to fix the prices of 39-odd formulations. The National Pharmaceutical Pricing Authority's (NPPA) order, issued on Wednesday, includes drug combinations such as ciprofloxacin hydrochloride, cefotaxime, paracetamol, domperidone and metformin + glimepiride and amoxicillin + potassium clavulanate.
3. [AdvaMed demands passage of D&C Amendment Bill to delineate medical devices from drugs](#) – Pharmabiz
The Advanced Medical Technology Association (AdvaMed), an association of medical device manufacturers in India, has demanded the passage of Drugs and Cosmetics Amendment Bill, delineating medical devices from drugs, in the upcoming monsoon session of parliament which is scheduled to begin from July 21.
4. [Grievances of chemists & druggists about DPCO-2013, Jan Aushadhi & online pharmacy are genuine: NPPA chief](#) – Pharmabiz.com
Chemists and druggists have genuine grievances on the need to modify the Drug Price Control Order (DPCO) 2013. The 8-lakh chemists and druggists located at every nook and corner of the country are apprehensive about their future with the Union government's move to open Jan Aushadhi stores which are dedicated low cost generic drug outlets and also the threat from online pharmacy trade practices, said Injeti Srinivas, chairman, National Pharmaceutical Pricing Authority (NPPA).

Others

1. [Digital health market in good shape, keeps VC funds flowing in](#) – The Business Line
The digital health market appears to be holding its own with venture capital funds flowing in rapidly this quarter, keeping pace with last year's growth. Though most bets by venture capitalists were on US-based healthcare companies in the second quarter, for the first time, nine Indian healthcare IT companies have received VC funding in a single quarter.
2. [Bogus healthcare](#) – The Telegraph
Jharkhand's medicine market is suddenly swamped with bogus antibiotic, antipyretic and analgesic drugs if the state laboratory in Ranchi is to be believed. Tests have, in no uncertain terms, confirmed widespread distribution and sale of counterfeit medicines across all the 24 districts, with prevalence most pronounced in East Singhbhum. Counterfeit drugs are usually either contaminated or contain the wrong ingredient. They may sometimes have the right active ingredient, but in the wrong dose, thus being both illegal and detrimental to health.